Emulation Differences vs. Biases When Calibrating Real-World Evidence Findings Against Randomized Controlled Trials

被引：35

作者：

Franklin, Jessica M. ^{[1
]}

Glynn, Robert J. ^{[1
]}

Suissa, Samy ^{[2
,3
,4
]}

Schneeweiss, Sebastian ^{[1
]}

机构：

[1] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02115 USA

[2] McGill Univ, Dept Epidemiol, Montreal, PQ, Canada

[3] McGill Univ, Dept Biostat, Montreal, PQ, Canada

[4] McGill Univ, Dept Occupat Hlth, Montreal, PQ, Canada

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2020年 / 107卷 / 04期

关键词：

D O I：

10.1002/cpt.1793

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Actionable real-world evidence (RWE) requires accurate estimation of causal treatment effects. Calibration of RWE against randomized controlled trials (RCTs) is sometimes done to demonstrate that RWE can support the same causal conclusion as RCTs. Disagreements can occur when studies in each pair asked different questions in different populations or due to the presence of residual bias. Distinguishing among reasons for differences will impact the level of confidence in RWE.

引用

页码：735 / 737

页数：3

共 50 条

[31] When and How Can Real World Data Analyses Substitute for Randomized Controlled Trials?
Franklin, Jessica M.
Schneeweiss, Sebastian
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 102 (06) : 924 - 933
[32] The feasibility of pragmatic influenza vaccine randomized controlled real-world trials in Denmark and England
Nealon, Joshua
Modin, Daniel
Ghosh, Rebecca E.
Rudin, Deborah
Gislason, Gunnar
Booth, Helen P.
Jensen, Jens Ulrik Staehr
Williams, Rachael
Shepherd, Hilary
Yelland, Eleanor
Bricout, Helene
Chaves, Sandra S.
Biering-Sorensen, Tor
NPJ VACCINES, 2022, 7 (01)
[33] The feasibility of pragmatic influenza vaccine randomized controlled real-world trials in Denmark and England
Joshua Nealon
Daniel Modin
Rebecca E. Ghosh
Deborah Rudin
Gunnar Gislason
Helen P. Booth
Jens Ulrik Stæhr Jensen
Rachael Williams
Hilary Shepherd
Eleanor Yelland
Helene Bricout
Sandra S. Chaves
Tor Biering-Sørensen
npj Vaccines, 7
[34] Comparison of statistical methods for integrating real-world evidence in a rare events meta-analysis of randomized controlled trials
Yao, Minghong
Wang, Yuning
Ren, Yan
Jia, Yulong
Zou, Kang
Li, Ling
Sun, Xin
RESEARCH SYNTHESIS METHODS, 2023, 14 (05) : 689 - 706
[35] Strengthening Real-World Evidence on Question Not Answered by Randomized Trials: A Trial Calibration Approach
Kirchgesner, Julien
Wang, Shirley V.
Schneeweiss, Sebastian
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 (09)
[36] A Comparative Analysis of Patient Characteristics in Cardiogenic Shock Trials: Differences Between Randomized Trials and Real-World Registries
Megaly, Michael
Buda, Kevin
Alaswad, Khaldoon
Brilakis, Emmanouil
Dupont, Allison
Naidu, Srihari
Ohman, Magnus
Napp, L. Christian
O'Neill, William
Basir, Mir
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 78 (19) : B12 - B12
[37] Empirical use of causal inference methods to evaluate survival differences in a real-world registry vs those found in randomized clinical trials
Lee, Hui-Jie
Wong, John B.
Jia, Beilin
Qi, Xinyue
DeLong, Elizabeth R.
STATISTICS IN MEDICINE, 2020, 39 (22) : 3003 - 3021
[38] Randomized Controlled Trials Versus Real World Evidence: Neither Magic Nor Myth
Eichler, Hans-Georg
Pignatti, Francesco
Schwarzer-Daum, Brigitte
Hidalgo-Simon, Ana
Eichler, Irmgard
Arlett, Peter
Humphreys, Anthony
Vamvakas, Spiros
Brun, Nikolai
Rasi, Guido
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 (05) : 1212 - 1218
[39] Editors' Introduction: Randomized Controlled Trials Meet the Real World: The Nature and Consequences of Null Findings
Herrington, Carolyn D.
Maynard, Rebecca
EDUCATIONAL RESEARCHER, 2019, 48 (09) : 577 - 579
[40] Randomized controlled trials and real-world evidence for market access and surveillance of high-risk products-The example of paclitaxel
Behrendt, C. -A.
Rother, U.
Ruemenapf, G.
Uhl, C.
Goertz, H.
Boeckler, D.
GEFASSCHIRURGIE, 2020, 25 (SUPPL 1): : 29 - 36

← 1 2 3 4 5 →